Merck & Kelun’s sac-TMT Combo Cuts Lung Cancer Progression Risk by 65% vs Keytruda

Positive Phase 3 data shows Merck and Kelun’s sac-TMT combined with Keytruda reduced the risk of progression or death by 65% vs Keytruda alone in first-line PD-L1+ NSCLC.